{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-116154","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.999296+00:00","generated_at":"2026-05-15T09:37:00.135956+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Eledon FY2025 net loss $45.6M; tegoprubart data shows insulin independence in T1D islet transplant","bullets":["Net loss for FY2025 was $45.6M ($0.52/share) vs $36.2M loss in FY2024; non-GAAP net loss (excl warrant gain) was $79.1M.","R&D expenses rose to $66.3M from $52.0M, driven by clinical trial expansion and manufacturing scale-up.","Phase 1b kidney transplant data: eGFR improved from 67.0 at 12mo to 74.2 at 24mo; no rejection or graft loss in 8 patients.","In T1D islet transplant study, all 10 patients >4 weeks post-transplant achieved 100% insulin independence with mean HbA1c ~5.35%.","Tegoprubart received FDA Orphan Drug designation for liver transplantation; Phase 3 kidney trial initiation pending FDA guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-116154","json":"https://secwatch.observer/filing/0001193125-26-116154.json","markdown":"https://secwatch.observer/filing/0001193125-26-116154.md","text":"https://secwatch.observer/filing/0001193125-26-116154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526116154/0001193125-26-116154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526116154/eldn-20260319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:37:00.135956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}